{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:00:04Z","timestamp":1776398404270,"version":"3.51.2"},"reference-count":156,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Anaesthesiology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.bpa.2013.02.004","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T03:04:21Z","timestamp":1366167861000},"page":"141-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Emerging haemostatic agents and patient blood management"],"prefix":"10.1016","volume":"27","author":[{"given":"Kenichi A.","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryl J.","family":"Kor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpa.2013.02.004_bib1","first-page":"805","article-title":"The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital","volume":"63","author":"Borgman","year":"2007","journal-title":"J Trauma"},{"key":"10.1016\/j.bpa.2013.02.004_bib2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/SLA.0b013e318185a9ad","article-title":"Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients","volume":"248","author":"Holcomb","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.bpa.2013.02.004_bib3","first-page":"221","article-title":"Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome","volume":"67","author":"Watson","year":"2009","journal-title":"J Trauma"},{"key":"10.1016\/j.bpa.2013.02.004_bib4","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1537-2995.2010.02753.x","article-title":"Development of a rapid emergency hemorrhage panel","volume":"50","author":"Chandler","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.bpa.2013.02.004_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1537-2995.2011.03241.x","article-title":"A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery","volume":"52","author":"Ogawa","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.bpa.2013.02.004_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-5223(94)70481-3","article-title":"Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation","volume":"107","author":"Despotis","year":"1994","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.bpa.2013.02.004_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1213\/00000539-199902000-00016","article-title":"Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery","volume":"88","author":"Shore-Lesserson","year":"1999","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bpa.2013.02.004_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00000542-200105000-00014","article-title":"Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass","volume":"94","author":"Nuttall","year":"2001","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bpa.2013.02.004_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/bja\/86.4.575","article-title":"Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass","volume":"86","author":"Royston","year":"2001","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bpa.2013.02.004_bib10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1034\/j.1399-6576.2001.450211.x","article-title":"On-site coagulation monitoring does not affect hemostatic outcome after cardiac surgery","volume":"45","author":"Capraro","year":"2001","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.bpa.2013.02.004_bib11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/bja\/aeh037","article-title":"Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery","volume":"92","author":"Avidan","year":"2004","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bpa.2013.02.004_bib12","doi-asserted-by":"crossref","first-page":"1117 e2","DOI":"10.1016\/j.jtcvs.2010.04.043","article-title":"Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial","volume":"140","author":"Girdauskas","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.bpa.2013.02.004_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000337183","article-title":"Patient blood management: a patient-orientated approach to blood replacement with the goal of reducing anemia, blood loss and the need for blood transfusion in elective surgery","volume":"39","author":"Gombotz","year":"2012","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.bpa.2013.02.004_bib14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/ALN.0b013e318254d1a3","article-title":"Patient blood management","volume":"116","author":"Goodnough","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bpa.2013.02.004_bib15","series-title":"Report of the US Department of Health and Human Services. The 2009 national blood collection and utilization survey report","year":"2011"},{"key":"10.1016\/j.bpa.2013.02.004_bib16","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1537-2995.2006.00891.x","article-title":"Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities","volume":"46","author":"Abdel-Wahab","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.bpa.2013.02.004_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmrv.2011.07.005","article-title":"Principles and practice of thromboelastography in clinical coagulation management and transfusion practice","volume":"26","author":"Bolliger","year":"2012","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.bpa.2013.02.004_bib18","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1046\/j.1537-2995.2002.00185.x","article-title":"The effectiveness of interventions to reduce physician's levels of inappropriate transfusion: what can be learned from a systematic review of the literature","volume":"42","author":"Wilson","year":"2002","journal-title":"Transfusion"},{"key":"10.1016\/j.bpa.2013.02.004_bib19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0140-6736(07)61199-4","article-title":"Coagulation factor concentrates: past, present, and future","volume":"370","author":"Key","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.bpa.2013.02.004_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tmrv.2006.11.001","article-title":"Modern plasma fractionation","volume":"21","author":"Burnouf","year":"2007","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.bpa.2013.02.004_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2141.2004.04972.x","article-title":"Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant","volume":"126","author":"O'Shaughnessy","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bpa.2013.02.004_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2141.2004.04973.x","article-title":"Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials","volume":"126","author":"Stanworth","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bpa.2013.02.004_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bpa.2009.09.007","article-title":"Perioperative coagulation management \u2013 fresh frozen plasma","volume":"24","author":"Kor","year":"2010","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"10.1016\/j.bpa.2013.02.004_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1537-2995.1961.tb00017.x","article-title":"Physiological basis for transfusion therapy in hemorrhagic disorders: a critical review","volume":"1","author":"Aggeler","year":"1961","journal-title":"Transfusion"},{"key":"10.1016\/j.bpa.2013.02.004_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.1987.tb02359.x","article-title":"Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient","volume":"67","author":"Ciavarella","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bpa.2013.02.004_bib26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00000542-198812000-00007","article-title":"Coagulation changes during packed red cell replacement of major blood loss","volume":"69","author":"Murray","year":"1988","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bpa.2013.02.004_bib27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/00000542-199603000-00032","article-title":"Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on blood component therapy","volume":"84","year":"1996","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bpa.2013.02.004_bib28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1365-2141.1998.00715.x","article-title":"Guidelines on oral anticoagulation: third edition","volume":"101","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bpa.2013.02.004_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2141.2004.04868.x","article-title":"Efficacy of standard dose and 30\u00a0ml\/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients","volume":"125","author":"Chowdary","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bpa.2013.02.004_bib30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1055\/s-0038-1655992","article-title":"Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy","volume":"77","author":"Makris","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1309\/NQXHUG7HND78LFFK","article-title":"Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results","volume":"126","author":"Holland","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.bpa.2013.02.004_bib32","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/j.1572-0241.2003.07467.x","article-title":"Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study","volume":"98","author":"Youssef","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpa.2013.02.004_bib33","first-page":"324","article-title":"Predicting hemorrhage using preoperative coagulation screening assays","volume":"3","author":"Dzik","year":"2004","journal-title":"Curr Hematol Rep"},{"key":"10.1016\/j.bpa.2013.02.004_bib34","doi-asserted-by":"crossref","first-page":"W15","DOI":"10.7326\/0003-4819-138-3-200302040-00011-w1","article-title":"Screening for the risk for bleeding or thrombosis","volume":"138","author":"Eckman","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bpa.2013.02.004_bib35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1537-2995.2005.00546.x","article-title":"Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review","volume":"45","author":"Segal","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.bpa.2013.02.004_bib36","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1097\/01.CCM.0000214288.88308.26","article-title":"Fresh frozen plasma and platelet transfusion for nonbleeding patients in the intensive care unit: benefit or harm?","volume":"34","author":"Gajic","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.bpa.2013.02.004_bib37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/jca.1025","article-title":"Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura","volume":"16","author":"Reutter","year":"2001","journal-title":"J Clin Apher"},{"key":"10.1016\/j.bpa.2013.02.004_bib38","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2007.06492.x","article-title":"The pathogenesis of transfusion-related acute lung injury (TRALI)","volume":"136","author":"Bux","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bpa.2013.02.004_bib39","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/01.CCM.0000214311.56231.23","article-title":"Pulmonary edema after transfusion: how to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury","volume":"34","author":"Gajic","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.bpa.2013.02.004_bib40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1537-2995.2008.01948.x","article-title":"Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma","volume":"49","author":"Chapman","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.bpa.2013.02.004_bib41","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1182\/blood-2011-08-370932","article-title":"Transfusion-related acute lung injury: incidence and risk factors","volume":"119","author":"Toy","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bpa.2013.02.004_bib42","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1537-2995.2010.02659.x","article-title":"A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States","volume":"50","author":"Kleinman","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.bpa.2013.02.004_bib43","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1537-2995.2010.02816.x","article-title":"Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients","volume":"51","author":"Li","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.bpa.2013.02.004_bib44","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1423-0410.2009.01206.x","article-title":"Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent\/detergent (S\/D)-treated plasma OctaplasLG","volume":"97","author":"Neisser-Svae","year":"2009","journal-title":"Vox Sang"},{"key":"10.1016\/j.bpa.2013.02.004_bib45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1423-0410.2009.01190.x","article-title":"Biochemical quality of the pharmaceutically licensed plasma OctaplasLG after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent\/detergent (S\/D) process time","volume":"97","author":"Heger","year":"2009","journal-title":"Vox Sang"},{"key":"10.1016\/j.bpa.2013.02.004_bib46","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/00000539-200205000-00012","article-title":"Fibrinolysis during liver transplantation is enhanced by using solvent\/detergent virus-inactivated plasma (ESDEP)","volume":"94","author":"de Jonge","year":"2002","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bpa.2013.02.004_bib47","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1213\/01.ANE.0000044044.61979.74","article-title":"Fibrinolysis during liver transplant and use of solvent\/detergent virus-inactivated plasma (ESDEP\/Octaplas)","volume":"96","author":"Solheim","year":"2003","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bpa.2013.02.004_bib48","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1053\/j.jvca.2006.01.016","article-title":"Transfusion triggers in orthotopic liver transplantation: a comparison of the thromboelastometry analyzer, the thromboelastogram, and conventional coagulation tests","volume":"20","author":"Coakley","year":"2006","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.bpa.2013.02.004_bib49","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/bja\/aeq022","article-title":"Rotation thromboelastometry detects thrombocytopenia and hypofibrinogenaemia during orthotopic liver transplantation","volume":"104","author":"Roullet","year":"2010","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bpa.2013.02.004_bib50","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1213\/01.ANE.0000044045.61979.3D","article-title":"Liver transplantation, solvent-detergent treated plasma and antifibrinolytics","volume":"96","author":"Ozier","year":"2003","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bpa.2013.02.004_bib51","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1423-0410.2007.00940.x","article-title":"Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura","volume":"93","author":"Scully","year":"2007","journal-title":"Vox Sang"},{"key":"10.1016\/j.bpa.2013.02.004_bib52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1423-0410.2003.00329.x","article-title":"Cost-effectiveness of solvent\/detergent-treated fresh-frozen plasma","volume":"85","author":"Riedler","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.bpa.2013.02.004_bib53","series-title":"Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis","author":"The Canadian Agency for Drugs and Technologies in Health","year":"2011"},{"key":"10.1016\/j.bpa.2013.02.004_bib54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/cc8937","article-title":"Freeze dried plasma: a French army specialty","volume":"14","author":"Daban","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.bpa.2013.02.004_bib55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tracli.2011.08.002","article-title":"Practice assessment in platelet transfusions","volume":"19","author":"Martinaud","year":"2012","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.bpa.2013.02.004_bib56","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/ALN.0b013e3181895bd8","article-title":"Perioperative hemostatic management of patients treated with vitamin K antagonists","volume":"109","author":"Levy","year":"2008","journal-title":"Anesthesiology"},{"issue":"Suppl. 2","key":"10.1016\/j.bpa.2013.02.004_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2004.00934.x","article-title":"FEIBA: mode of action","volume":"10","author":"Turecek","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.bpa.2013.02.004_bib58","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-2141.2005.05917.x","article-title":"Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy","volume":"132","author":"Sarode","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bpa.2013.02.004_bib59","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1537-2995.2008.02080.x","article-title":"Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose","volume":"49","author":"Holland","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.bpa.2013.02.004_bib60","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1160\/TH11-04-0240","article-title":"A comparative study of prothrombin complex concentrates and fresh-frozen plasma for warfarin reversal under static and flow conditions","volume":"106","author":"Ogawa","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2007.02.009","article-title":"Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation","volume":"121","author":"Riess","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.bpa.2013.02.004_bib62","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2008.02904.x","article-title":"Prothrombin complex concentrate (Beriplex P\/N) for emergency anticoagulation reversal: a prospective multinational clinical trial","volume":"6","author":"Pabinger","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib63","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.gassur.2003.10.014","article-title":"Successful perioperative management of factor X deficiency associated with primary amyloidosis","volume":"8","author":"Takabe","year":"2004","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.bpa.2013.02.004_bib64","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2516.2005.01141.x","article-title":"Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision","volume":"11","author":"Dargaud","year":"2005","journal-title":"Haemophilia"},{"key":"10.1016\/j.bpa.2013.02.004_bib65","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/ALN.0b013e318238c036","article-title":"Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model","volume":"116","author":"Godier","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bpa.2013.02.004_bib66","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.bpa.2013.02.004_bib67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/bja\/aes502","article-title":"On the reversal of new oral anti-coagulants: can we simply extrapolate data from the animal models to humans?","volume":"110","author":"Tanaka","year":"2013","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bpa.2013.02.004_bib68","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ajh.21046","article-title":"Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature","volume":"83","author":"Leissinger","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bpa.2013.02.004_bib69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.mbc.0000114437.81125.2b","article-title":"Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates","volume":"15","author":"Dusel","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.bpa.2013.02.004_bib70","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1172\/JCI113475","article-title":"Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation","volume":"81","author":"D'Angelo","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bpa.2013.02.004_bib71","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698","article-title":"A common genetic variation in the 3\u2032-untranslated region of the prothrombin gene is\u00a0associated with elevated plasma prothrombin levels and an increase in venous thrombosis","volume":"88","author":"Poort","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bpa.2013.02.004_bib72","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2141.1993.tb03065.x","article-title":"Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate","volume":"84","author":"Hampton","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bpa.2013.02.004_bib73","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2141.1993.tb03078.x","article-title":"Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy","volume":"84","author":"Ohga","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bpa.2013.02.004_bib74","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2516.2007.01594.x","article-title":"Factor VIII inhibitor bypassing activity (FEIBA) \u2013 addressing safety issues","volume":"14","author":"Aledort","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.bpa.2013.02.004_bib75","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199909093411104","article-title":"The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation","volume":"341","author":"De Stefano","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpa.2013.02.004_bib76","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1067\/mtc.2002.126038","article-title":"Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII","volume":"124","author":"Bui","year":"2002","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.bpa.2013.02.004_bib77","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1213\/ane.0b013e3181608f7c","article-title":"Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass","volume":"106","author":"Sniecinski","year":"2008","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bpa.2013.02.004_bib78","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1213\/ane.0b013e3181618702","article-title":"Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma","volume":"106","author":"Szlam","year":"2008","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bpa.2013.02.004_bib79","first-page":"419","article-title":"Cross-sectional guidelines for therapy with blood components and plasma derivatives: chapter 7 procoagulators","volume":"36","year":"2009","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.bpa.2013.02.004_bib80","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/blood-2009-06-225706","article-title":"A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion","volume":"114","author":"Kleinman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bpa.2013.02.004_bib81","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3324\/haematol.11072","article-title":"Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection","volume":"92","author":"Pereira","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bpa.2013.02.004_bib82","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2516.2011.02548.x","article-title":"Clinical pharmacological study of a plasma-derived factor VIIa and factor X\u00a0mixture (MC710) in haemophilia patients with inhibitors \u2013 phase I trial","volume":"18","author":"Shirahata","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.bpa.2013.02.004_bib83","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/hae.12024","article-title":"Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors-phase I trial: 2nd report","volume":"19","author":"Shirahata","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.bpa.2013.02.004_bib84","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.thromres.2009.12.010","article-title":"Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in\u00a0vitro assessment of FVIIa\/FX mixture as an alternative bypassing agent","volume":"125","author":"Nakatomi","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.bpa.2013.02.004_bib85","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1538-7836.2011.04211.x","article-title":"Prothrombin complex concentrate and recombinant prothrombin alone or in combination with recombinant factor X and FVIIa in dilutional coagulopathy: a porcine model","volume":"9","author":"Mitterlechner","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib86","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1172\/JCI110939","article-title":"Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors","volume":"71","author":"Hedner","year":"1983","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.bpa.2013.02.004_bib87","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-2001-16890","article-title":"Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development","volume":"27","author":"Jurlander","year":"2001","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib88","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1538-7836.2012.04793.x","article-title":"Mechanisms and monitoring of bypassing agent therapy","volume":"10","author":"Hoffman","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2008.01931.x","article-title":"Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.bpa.2013.02.004_bib90","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bpa.2013.02.004_bib91","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1042\/bj2650327","article-title":"The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII","volume":"265","author":"Bom","year":"1990","journal-title":"Biochem J"},{"key":"10.1016\/j.bpa.2013.02.004_bib92","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.V75.5.1069.1069","article-title":"Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa","volume":"75","author":"Rao","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bpa.2013.02.004_bib93","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2141.1997.4463256.x","article-title":"Platelet activity of high-dose factor VIIa is independent of tissue factor","volume":"99","author":"Monroe","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bpa.2013.02.004_bib94","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.V95.4.1330.004k28_1330_1335","article-title":"Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa","volume":"95","author":"van't Veer","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bpa.2013.02.004_bib95","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.CCM.0000159087.85970.38","article-title":"Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review","volume":"33","author":"Levi","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.bpa.2013.02.004_bib96","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.4065\/79.12.1495","article-title":"Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage","volume":"79","author":"Freeman","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bpa.2013.02.004_bib97","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/S0016-5085(97)70013-1","article-title":"Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study","volume":"113","author":"Bernstein","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpa.2013.02.004_bib98","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/bja\/aei244","article-title":"Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study","volume":"95","author":"Diprose","year":"2005","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bpa.2013.02.004_bib99","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(03)12268-4","article-title":"Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial","volume":"361","author":"Friederich","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.bpa.2013.02.004_bib100","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(99)05155-7","article-title":"Treatment of traumatic bleeding with recombinant factor VIIa","volume":"354","author":"Kenet","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.bpa.2013.02.004_bib101","first-page":"1174","article-title":"Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII","volume":"101","author":"Bouwmeester","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpa.2013.02.004_bib102","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1213\/ANE.0b013e3181c039e6","article-title":"Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry","volume":"109","author":"Phillips","year":"2009","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bpa.2013.02.004_bib103","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.TA.0000171453.37949.B7","article-title":"Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials","volume":"59","author":"Boffard","year":"2005","journal-title":"J Trauma"},{"key":"10.1016\/j.bpa.2013.02.004_bib104","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.108.834275","article-title":"Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery","volume":"120","author":"Gill","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.bpa.2013.02.004_bib105","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/hep.22216","article-title":"Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial","volume":"47","author":"Bosch","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.bpa.2013.02.004_bib106","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00000542-200502000-00006","article-title":"Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial","volume":"102","author":"Lodge","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bpa.2013.02.004_bib107","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.mbc.0000233369.03358.c1","volume":"17","author":"Ekert","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.bpa.2013.02.004_bib108","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa042991","article-title":"Recombinant activated factor VII for acute intracerebral hemorrhage","volume":"352","author":"Mayer","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpa.2013.02.004_bib109","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa0707534","article-title":"Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage","volume":"358","author":"Mayer","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpa.2013.02.004_bib110","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.thromres.2006.05.011","article-title":"Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation","volume":"119","author":"Dickneite","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.bpa.2013.02.004_bib111","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2009-11-253492","article-title":"Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects","volume":"116","author":"Skolnick","year":"2010","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.bpa.2013.02.004_bib112","first-page":"45S","article-title":"Reversal of drug-induced anticoagulation: old solutions and new problems","volume":"52","author":"Dzik","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.bpa.2013.02.004_bib113","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2011-11-393587","article-title":"Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding","volume":"119","author":"Warkentin","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bpa.2013.02.004_bib114","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3171\/2012.2.JNS112132","article-title":"Neurosurgical complications of direct thrombin inhibitors \u2013 catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran","volume":"116","author":"Garber","year":"2012","journal-title":"J Neurosurg"},{"key":"10.1016\/j.bpa.2013.02.004_bib115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jama.295.3.293","article-title":"Thromboembolic adverse events after use of recombinant human coagulation factor VIIa","volume":"295","author":"O'Connell","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.bpa.2013.02.004_bib116","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1006221","article-title":"Safety of recombinant activated factor VII in randomized clinical trials","volume":"363","author":"Levi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpa.2013.02.004_bib117","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jocn.2009.11.020","article-title":"A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia","volume":"17","author":"Yuan","year":"2010","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.bpa.2013.02.004_bib118","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1053\/j.jvca.2011.03.004","article-title":"Recombinant activated factor VII increases stroke in cardiac surgery: a meta-analysis","volume":"25","author":"Ponschab","year":"2011","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.bpa.2013.02.004_bib119","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1160\/TH07-08-0525","article-title":"Prolonged in-vivo half-life of factor VIIa by fusion to albumin","volume":"99","author":"Weimer","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib120","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1021\/bi001612z","article-title":"Substitution of aspartic acid for methionine-306 in factor VIIa abolishes the allosteric linkage between the active site and the binding interface with tissue factor","volume":"40","author":"Persson","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.bpa.2013.02.004_bib121","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2011.04223.x","article-title":"Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity","volume":"9","author":"Hoffman","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib122","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.thromres.2011.04.009","article-title":"Recombinant factor VIIa analog NN1731 (V158D\/E296V\/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma","volume":"128","author":"Gray","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.bpa.2013.02.004_bib123","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1538-7836.2008.03253.x","article-title":"Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects","volume":"7","author":"Moss","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib124","series-title":"RiaSTAP, fibrinogen concentrate (human)","author":"Behring","year":"2011"},{"key":"10.1016\/j.bpa.2013.02.004_bib125","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1538-7836.2006.02014.x","article-title":"Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia","volume":"4","author":"Peyvandi","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib126","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1053\/j.jvca.2009.07.012","article-title":"In\u00a0vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma","volume":"24","author":"Rumph","year":"2010","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"Suppl. 2","key":"10.1016\/j.bpa.2013.02.004_bib127","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0049-3848(09)70159-8","article-title":"Cryoprecipitate: no longer the best therapeutic choice in congenital fibrinogen disorders?","volume":"124","author":"Bevan","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.bpa.2013.02.004_bib128","first-page":"S79","article-title":"The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital","volume":"64","author":"Stinger","year":"2008","journal-title":"J Trauma"},{"key":"10.1016\/j.bpa.2013.02.004_bib129","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1537-2995.2008.02029.x","article-title":"Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage","volume":"49","author":"Lewis","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.bpa.2013.02.004_bib130","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1053\/j.jvca.2010.02.018","article-title":"Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest","volume":"24","author":"Sniecinski","year":"2010","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.bpa.2013.02.004_bib131","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1365-2141.2010.08208.x","article-title":"A critical evaluation of cryoprecipitate for replacement of fibrinogen","volume":"149","author":"Sorensen","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bpa.2013.02.004_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1538-7836.2010.04099.x","article-title":"For: fibrinogen concentrate for management of bleeding","volume":"9","author":"Rahe-Meyer","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib133","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/j.1538-7836.2011.04424.x","article-title":"Fibrinogen replacement therapy for congenital fibrinogen deficiency","volume":"9","author":"Bornikova","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib134","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.transci.2004.04.003","article-title":"Pharmacokinetic properties of a pasteurised fibrinogen concentrate","volume":"32","author":"Kreuz","year":"2005","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.bpa.2013.02.004_bib135","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/j.1538-7836.2009.03633.x","article-title":"Pharmacokinetics and safety of fibrinogen concentrate","volume":"7","author":"Manco-Johnson","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib136","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/01.TA.0000156246.53383.9F","article-title":"Independent contributions of hypothermia and acidosis to coagulopathy in swine","volume":"58","author":"Martini","year":"2005","journal-title":"J Trauma"},{"key":"10.1016\/j.bpa.2013.02.004_bib137","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/bja\/aep098","article-title":"Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in\u00a0vitro model","volume":"102","author":"Bolliger","year":"2009","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bpa.2013.02.004_bib138","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/ALN.0b013e318264c644","article-title":"Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients","volume":"117","author":"Weber","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bpa.2013.02.004_bib139","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/bja\/aeq058","article-title":"Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery","volume":"104","author":"Solomon","year":"2010","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bpa.2013.02.004_bib140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1423-0410.2007.01024.x","article-title":"Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding","volume":"94","author":"Danes","year":"2008","journal-title":"Vox Sang"},{"key":"10.1016\/j.bpa.2013.02.004_bib141","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-3148.2008.00854.x","article-title":"Fibrinogen concentrate for acquired hypofibrinogenaemic states","volume":"18","author":"Weinkove","year":"2008","journal-title":"Transfus Med"},{"key":"10.1016\/j.bpa.2013.02.004_bib142","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(99)01264-7","article-title":"Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints","volume":"354","author":"Levi","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.bpa.2013.02.004_bib143","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/j.1538-7836.2012.04823.x","article-title":"Comparable effect of recombinant and plasma-derived human fibrinogen concentrate on ex\u00a0vivo clot formation after cardiac surgery","volume":"10","author":"Radulovic","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib144","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V100.1.148","article-title":"Thrombin functions during tissue factor-induced blood coagulation","volume":"100","author":"Brummel","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bpa.2013.02.004_bib145","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1152\/physrev.00016.2010","article-title":"Factor XIII: a coagulation factor with multiple plasmatic and cellular functions","volume":"91","author":"Muszbek","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bpa.2013.02.004_bib146","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1172\/JCI109671","article-title":"Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor","volume":"65","author":"Sakata","year":"1980","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bpa.2013.02.004_bib147","doi-asserted-by":"crossref","first-page":"27220","DOI":"10.1074\/jbc.273.42.27220","article-title":"Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin","volume":"273","author":"Valnickova","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bpa.2013.02.004_bib148","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1365-2516.2002.00633.x","article-title":"Rare coagulation deficiencies","volume":"8","author":"Peyvandi","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.bpa.2013.02.004_bib149","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1055\/s-0029-1225765","article-title":"Factor XIII deficiency","volume":"35","author":"Karimi","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib150","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1213\/01.ANE.0000123012.24871.62","article-title":"The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography","volume":"99","author":"Nielsen","year":"2004","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bpa.2013.02.004_bib151","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/ALN.0b013e318194b21e","article-title":"Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding","volume":"110","author":"Korte","year":"2009","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bpa.2013.02.004_bib152","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1538-7836.2004.00728.x","article-title":"Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency","volume":"2","author":"Lim","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.bpa.2013.02.004_bib153","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2011-10-386045","article-title":"Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency","volume":"119","author":"Inbal","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bpa.2013.02.004_bib154","series-title":"Fibrogammin P, FXIII concentrate (human)","author":"Behring","year":"2010"},{"key":"10.1016\/j.bpa.2013.02.004_bib155","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/01.STR.0000017219.83330.FF","article-title":"Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study","volume":"33","author":"Gerlach","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.bpa.2013.02.004_bib156","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-2005-872853","article-title":"Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation","volume":"54","author":"Godje","year":"2006","journal-title":"Thorac Cardiovasc Surg"}],"updated-by":[{"DOI":"10.1016\/j.bpa.2013.04.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000}}],"container-title":["Best Practice & Research Clinical Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521689613000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521689613000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:33:48Z","timestamp":1776396828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521689613000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":156,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1521689613000207"],"URL":"https:\/\/doi.org\/10.1016\/j.bpa.2013.02.004","relation":{},"ISSN":["1753-3740"],"issn-type":[{"value":"1753-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging haemostatic agents and patient blood management","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Anaesthesiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpa.2013.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}